Umekita Shinya, Kiyozawa Daisuke, Honma Hitoshi, Kohashi Kenichi, Taniguchi Yoshiaki, Kawatoko Shinichiro, Sasaki Taisuke, Ihara Eikichi, Oki Eiji, Nakamura Masafumi, Ogawa Yoshihiro, Oda Yoshinao
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan.
Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Gastric Cancer. 2025 May;28(3):455-464. doi: 10.1007/s10120-025-01589-8. Epub 2025 Feb 17.
The role of janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling remains unclear in gastric solid-type poorly differentiated adenocarcinoma. The present study investigates the clinicopathological significance of JAK2, STAT3, and STAT4 expression in solid-type poorly differentiated adenocarcinoma.
We retrospectively enrolled 102 participants with primary solid-type poorly differentiated adenocarcinoma. We categorized participants according to deficient or proficient mismatch repair status (46 and 56 participants, respectively). Expression of phosphorylated JAK2 (pJAK2), phosphorylated STAT3 (pSTAT3), and STAT4 were analyzed via immunohistochemistry. We analyzed differences in protein expression in relation to mismatch repair status, and associations of high/low protein expression with clinicopathological characteristics and prognoses.
Deficient mismatch repair was found to be associated with high pJAK2 (p = 0.038) and STAT4 (p = 0.023) expression in contrast to proficient mismatch repair. Log-rank analysis revealed high pSTAT3 and low STAT4 expression to be significantly correlated with reduced overall survival (p = 0.001). Multivariate analysis revealed high pSTAT3 and low STAT4 expression to be independent indicators of unfavorable prognosis (hazard ratio = 2.751, p = 0.030), as was proficient mismatch repair status (hazard ratio = 3.819, p = 0.012).
High expression of pJAK2 and STAT4 is more frequent in deficient compared with proficient mismatch repair in solid-type poorly differentiated adenocarcinoma. High pSTAT3 and low STAT4 expression could be a useful prognostic indicator in solid-type poorly differentiated adenocarcinoma.
在胃实性低分化腺癌中,Janus激酶(JAK)/信号转导子和转录激活子(STAT)信号通路的作用仍不明确。本研究探讨JAK2、STAT3和STAT4表达在实性低分化腺癌中的临床病理意义。
我们回顾性纳入了102例原发性实性低分化腺癌患者。根据错配修复状态缺陷或完善将患者分类(分别为46例和56例)。通过免疫组织化学分析磷酸化JAK2(pJAK2)、磷酸化STAT3(pSTAT3)和STAT4的表达。我们分析了与错配修复状态相关的蛋白表达差异,以及高/低蛋白表达与临床病理特征和预后的关联。
与错配修复完善相比,错配修复缺陷与高pJAK2(p = 0.038)和STAT4(p = 0.023)表达相关。对数秩分析显示,高pSTAT3和低STAT4表达与总生存期缩短显著相关(p = 0.001)。多变量分析显示,高pSTAT3和低STAT4表达是不良预后的独立指标(风险比 = 2.751,p = 0.030),错配修复完善状态也是如此(风险比 = 3.819,p = 0.012)。
在实性低分化腺癌中,与错配修复完善相比,错配修复缺陷中pJAK2和STAT4的高表达更为常见。高pSTAT3和低STAT4表达可能是实性低分化腺癌有用的预后指标。